Luca Valenti

Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty L...

• Current Pharmaceutical Design
• April 2020

Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update

• Current Pharmaceutical Design
• February 2019

Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver dis...

• Liver International
• October 2018

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat...

• Hepatology Communications
• April 2018

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoh...

• Journal of Internal Medicine
• December 2017

Mutant PNPLA3 I148M protein as pharmacological target for liver disease

• Hepatology
• August 2017

Hepatic iron is the major determinant of serum ferritin in NAFLD patients

• Liver International
• July 2017

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in pat...

• Cancer Medicine
• July 2017

Editorial: new insights into the relationship between the intestine and non-alcoholic f...

• Alimentary Pharmacology & Therapeutics (Suppl)
• July 2017

Fibronectin Type III Domain–Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and L...

• The Journal of Clinical Endocrinology & Metabolism
• May 2017

Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?

• Liver International
• June 2016

Hepcidin resistance in dysmetabolic iron overload

• Liver International
• April 2016

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 ex...

• Hepatology
• January 2016

Reply

• Hepatology
• July 2015

Reply

• Hepatology
• June 2015

Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver ...

• Hepatology
• May 2015

Particulate matter phagocytosis induces tissue factor in differentiating macrophages

• Journal of Applied Toxicology
• April 2015

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepat...

• Hepatology
• January 2015

The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatoh...

• Liver International
• November 2014

Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independe...

• European Journal of Clinical Investigation
• June 2014

CDKN1A: A double-edged sword in fatty liver?

• Cell Cycle
• April 2014

Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patient...

• Hepatology
• August 2013

PNPLA3 Ile148Met variant and hepatocellular carcinoma: A matter of fat

• Digestive and Liver Disease
• December 2012

I148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology

• Hepatology
• June 2012

Iron and the Adipocyte: Beware the Liver!

• ImmunoGastroenterology
• January 2012

Diagnostic and therapeutic implications of the association between ferritin level and s...

• World Journal of Gastroenterology
• January 2012

Patatin-like phospholipase domain containing-3gene I148M polymorphism, steatosis, and l...

• World Journal of Gastroenterology
• January 2012

Modulation of Iron Metabolism and Hepcidin Release by HFE Mutations in Chronic Hemodial...

• November 2011

PNPLA3 I148M polymorphism and liver damage in obese children

• The Journal of Pediatrics
• November 2011

Patatin-like phospholipase domain-containing protein 3 genotype and hepatocellular carc...

• Hepatology
• April 2011

Reply

• Hepatology
• March 2010

Reply:

• Hepatology
• December 2008

Risk of severe liver disease in nonalcoholic fatty liver disease: Role of insulin resis...

• Hepatology
• November 2008

HFEmutations in nonalcoholic fatty liver disease

• Hepatology
• April 2008

Turning up the heat in the fat cell

• news nature com
• November 2004

Effect of iron depletion in patients with nonalcoholic fatty liver disease without carb...

• Gastroenterology
• March 2003

TNFα Promoter Polymorphisms